PLRX
Pliant Therapeutics Inc
NASDAQ · Pharmaceuticals
$1.14
+0.05 (+4.59%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 15.16M | 13.79M | 14.54M |
| Net Income | 3.08M | 2.65M | 3.08M |
| EPS | — | — | — |
| Profit Margin | 20.3% | 19.2% | 21.2% |
| Rev Growth | +19.0% | -9.0% | -2.1% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 7.24M | 6.72M | 6.69M |
| Total Equity | 21.05M | 21.35M | 19.82M |
| D/E Ratio | 0.34 | 0.31 | 0.34 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 5.59M | 4.59M | 4.96M |
| Free Cash Flow | 2.06M | 2.45M | 2.36M |